Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal

This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures.